Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28870451 | 0.81 | HTT (0.31) | ALDH1A1HPGD | |
| SCHEMBL25518362 | 0.79 | ALDH1A1 (0.40) | CYP1A2ALDH1A1KDM4EGPR174 | |
| SCHEMBL4264946 | 0.79 | POLB (0.54) | SMN1; SMN2 | |
| SCHEMBL25517550 | 0.78 | CHRNB2 (0.45) | CYP1A2TDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL16136078 | 0.74 | HPGD (0.53) | EPHX1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL30674690 | 0.73 | HTT (0.30) | — | |
| SCHEMBL12658989 | 0.73 | NCF1 (0.36) | ALDH1A1HPGD | |
| SCHEMBL329321 | 0.72 | CYP1A2 (0.52) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL18763886 | 0.72 | EPHX2 (0.38) | EPHX2EPHX1CYP1A2TDP1ALDH1A1 | |
| SCHEMBL4550276 | 0.70 | SMN1; SMN2 (0.52) | EPHX2EPHX1CYP1A2TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115698035-A | Inhibitors of norovirus and coronavirus replication | 共晶制药公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | EPHX2 4754/4885EPHX1 4282/4885CYP1A2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.